Detailed description page of ThPDB2
| This page displays user query in tabular form. |
Th1492 details |
| Primary information | |
|---|---|
| ID | 14350 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Amino Acids, Peptides, and Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14351 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Biological Factors |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14352 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Cytokines |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14353 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Intercellular Signaling Peptides and Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14354 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Peptides |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14355 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 14356 |
| Therapeutic ID | Th1492 |
| Protein Name | Dulanermin |
| Sequence | >Th1492_Dulanermin VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSELSNLHLRNGELVIHEKGFYYEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG |
| Molecular Weight | 19492.7851 |
| Chemical Formula | C871H1329N243O260S4 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. |
| Indication/Disease | NA |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA | |
| Clearance | NA |
| Categories | Recombinant Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |